Generic drug maker Mylan Inc. said that its fourth-quarter profit fell 38 percent on higher costs and charges, but adjusted results meet Wall Street expectations.
Upsher-Smith Laboratories is voluntarily expanding its previously announced recall of Jantoven Warfarin Sodium, USP, 3 mg Tablets to include additional products that were packaged on the same packaging line between May 17, 2010 and November 17, 2010.
Abbott Laboratories said a federal court of appeals has overturned a $1.67 billion judgment against the company related to patents on its best-selling drug Humira, which were challenged by rival Johnson & Johnson.
President Barack Obama, in his State of the Union address, identified biomedical research a key industry segment in need of "an investment that will strengthen our security, protect our planet, and create countless new jobs for our people.
Accelrys, Inc., a leading scientific informatics software and services company, announced its entrance in the rapidly growing next generation sequencing (NGS) market with the release of the NGS Collection for Pipeline Pilot.
Genedata announced the release of Genedata Biologics, a first-in-class, off-the-shelf software solution for comprehensive data management and analysis of biologics R&D activities.
Sheffield Bio-Science has formed a strategic alliance with Wockhardt Ltd. Under this partnership, Sheffield Bio-Science will be the exclusive global sales and distribution partner for recombinant insulin manufactured by global Indian biotech Wockhardt.
Quanterix Corporation announced that it has entered into an evaluation of agreement with Novartis Diagnostics on the potential use of Quanterix’s Single Molecule Array (SiMoA) platform technology for diagnostic use.
Researchers have developed a simple method of making short protein chains with spiral structures that can also dissolve in water, these structures could have applications as building blocks for self-assembling nanostructures and as agents for drug and gene delivery.
A cancer-causing retrovirus exploits key proteins in its host cells to extend the life of those cells, thereby prolonging its own survival and ability to spread.
Dynavax Technologies Corporation announced that the Data Safety Monitoring Board (DSMB) established for Dynavax's two ongoing Phase 3 trials for HEPLISAV has completed its planned safety assessments.
Bristol-Myers Squibb Company and AstraZeneca announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.
Phenomenex Inc. and Shimadzu Scientific Instruments announced a marketing collaboration for LC and GC systems. Through this collaboration, Shimadzu systems and Phenomenex columns will be offered together as a complete solution.
Scientists who examined more than 10,000 chemical compounds during the last year in search of potential new drugs for a group of untreatable brain diseases, are reporting that one substance shows unusual promise.
Somaxon Pharmaceuticals Inc. said it received a new patent on its insomnia drug Silenor, extending its exclusivity on the drug. The company said the U.S. Patent and Trademark Office awarded it a patent that will expire no earlier than July 2027.